Uduak Grace Thomas on Muck Rack

Uduak Grace Thomas

New York
As seen in: Mary Ann Liebert, Inc., Taylor & Francis Online, Flipboard, Genetic Engineering & Biotechnology News, GenomeWeb, Inside Precision Medicine, Drug Discovery World
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Uduak Grace

Contact Uduak Grace, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics

|
By Uduak Grace Thomas
| Genetic Engineering & Biotechnology News Verified
Home Topics Drug Discovery Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics Inflammatory bowel disease (illustration). [Christoph Burgstedt/Science Photo Library/Getty Images] Though he is trained as a gastroenterologist and scientist, Frédéric Marrache, MD, PhD, has always had something of an entrepreneurial itch.
Open in Who Shared Issue with article?

BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development

|
By Uduak Grace Thomas
| Genetic Engineering & Biotechnology News Verified
Home Topics Drug Discovery BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development Panelists during the FDA town hall at BIO 2026. (L to R) Lowell Zeta, JD, acting chief of staff at the FDA; Karim Mikhail, CBER acting director; Michael Davis, MD, PhD, CDER acting director [Uduak Thomas] SAN DIEGO — The U.S. Food and Drug Administration (FDA) is in the middle of a cultural and operational shift that goes beyond leadership changes.
Open in Who Shared Issue with article?

Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

|
By Alex Philippidis Verified, Uduak Grace Thomas, Fay Y. Lin Verified, Corinna Singleman Verified
| Genetic Engineering & Biotechnology News Verified
We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates.
Open in Who Shared Issue with article?
See all 437 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified